Cholera Cases Surge Globally, Exceeding Last Year’s Toll and Highlighting a Political Crisis
Table of Contents
Despite being a historically preventable disease, cholera is experiencing a dramatic resurgence, with 6,800 deaths reported in 32 countries so far this year – already surpassing the 6,000 deaths recorded in all of 2023, which itself represented a 50% increase from 2022. While largely eradicated in industrialized nations – the last outbreak in Britain occurred in 1866, and the United States has not seen an outbreak since 1911 – the disease is now a stark reality for vulnerable populations worldwide.
A Disease of Deprivation and Conflict
The most severe outbreaks are currently concentrated in Africa, where ongoing conflict is not only accelerating the spread of cholera but also actively hindering control efforts. Experts emphasize that cholera is fundamentally “the definitive disease of deprivation,” persisting not due to a lack of scientific understanding or viable solutions, but because of a critical failure of political will.
Global Response Efforts and Existing Infrastructure
A collaborative effort involving more than 50 partners, spearheaded by the World Health Organization (WHO), is actively responding to these outbreaks through the Global Task Force on Cholera Control. Established in 1992, the task force focuses on ensuring access to essential supplies, bolstering detection and prevention strategies, and coordinating global priorities for sustainable disease control. Complementing this work, the WHO and the Africa Centres for Disease Control and Prevention launched a continental cholera emergency response plan in August.
Understanding Cholera and its Prevention
Cholera is caused by ingesting food or water contaminated with the bacterium Vibrio cholerae, typically spread through fecal matter. The most effective preventative measure is ensuring access to safe water and sanitation – a reality in developed countries, but a significant challenge for communities grappling with inequality, poverty, conflict, displacement, and climate-related disasters.
Vaccine Shortages and the Strain on Supply
Effective cholera vaccines exist, with oral formulations superseding earlier injectable versions developed in the late 19th century. However, limited market incentive – as the disease primarily affects the world’s poorest – has resulted in a reliance on a single manufacturer capable of producing vaccines at the necessary scale: EUBiologics, based in South Korea.
To facilitate rapid and equitable access to vaccines during emergencies, the WHO and partners established a global cholera vaccine stockpile in 2013, managed by the International Coordinating Group on Vaccine Provision (ICG). Since its inception, the stockpile has distributed nearly 255 million doses to 34 countries. Notably, approximately 75% of these doses have been distributed since 2021, reflecting the recent global resurgence. As of this year, over 49 million doses have already been disbursed, exceeding previous annual records.
A Temporary Fix: Single-Dose Vaccination
Given the increasing frequency and severity of outbreaks, the current vaccine supply is insufficient for preventative campaigns, focusing instead on outbreak control. The stockpile is regularly replenished, but production consistently struggles to meet demand, often falling below the recommended threshold of 5 million doses. In an effort to stretch limited supplies, the ICG suspended the standard two-dose vaccination regimen in 2022, opting for a single-dose approach. This decision was based on evidence demonstrating that a single dose provides some protection, although it wanes more quickly than the immunity conferred by two doses. This single-dose strategy is therefore considered a temporary measure.
Expanding Production and Long-Term Solutions
Demand for the vaccine shows no signs of decreasing, necessitating increased production capacity. In October 2024, Zambia signed a memorandum of understanding with China’s Jijia Medical Technology Company to establish a cholera vaccine production facility in Lusaka. However, any locally manufactured doses will require rigorous quality assurance and clinical trials before receiving WHO approval and being deployed in mass vaccination campaigns.
While expanding vaccine production in Africa is crucial, the long-term solution lies in governmental investment in safe drinking water and sanitation infrastructure. As one analyst noted, “Cholera is not a scientific or medical challenge; it’s a political one.” Unlike diseases such as Alzheimer’s and most cancers, which may not be entirely preventable, cholera can be stopped. Its persistence is directly linked to the persistence of poverty, inequality, conflict, and displacement.
